alpha-synuclein has been researched along with 1-2-4-triazole* in 2 studies
2 other study(ies) available for alpha-synuclein and 1-2-4-triazole
| Article | Year |
|---|---|
Discovery of Neuroprotective Agents Based on a 5-(4-Pyridinyl)-1,2,4-triazole Scaffold.
Parkinson's disease (PD) is characterized by the death of dopaminergic neurons. The common histopathological hallmark in PD patients is the formation of intracellular proteinaceous accumulations. The main constituent of these inclusions is alpha-synuclein (α-syn), an intrinsically disordered protein that in pathological conditions creates amyloid aggregates that lead to neurotoxicity and neurodegeneration. The main goal of our study was to optimize our previously identified α-syn aggregation inhibitors of 5-(4-pyridinyl)-1,2,4-triazole chemotype in terms of in vivo efficacy. Our efforts resulted in the identification of ethyl 2-((4-amino-5-(pyridin-4-yl)-4 Topics: alpha-Synuclein; Dopaminergic Neurons; Humans; Neuroprotective Agents; Parkinson Disease; Triazoles | 2022 |
Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease.
Parkinson's disease is one of the most common neurodegenerative disorders in elderly age. One of the mechanisms involved in the neurodegeneration appears related to the aggregation of the presynaptic protein alpha synuclein (α-syn) into toxic oligomers and fibrils. To date, no highly effective treatment is currently available; therefore, there is an increasing interest in the search of new therapeutic tools. The modulation of α-syn aggregation represents an emergent and promising disease-modifying strategy for reducing or blocking the neurodegenerative process. Herein, by combining Topics: alpha-Synuclein; Amines; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Neuroprotective Agents; Parkinson Disease; Protein Aggregates; Small Molecule Libraries; Structure-Activity Relationship; Triazoles | 2020 |